Next Article in Journal
Apparent Motion Perception in the Praying Mantis: Psychophysics and Modelling
Next Article in Special Issue
Ex Vivo Hyperspectral Autofluorescence Imaging and Localization of Fluorophores in Human Eyes with Age-Related Macular Degeneration
Previous Article in Journal
Special Issue for Purinergic Receptors, Particularly P2X7 Receptor, in the Eye
Previous Article in Special Issue
Image Stabilization in Central Vision Loss: The Horizontal Vestibulo-Ocular Reflex
Article Menu

Export Article

Open AccessReview
Vision 2018, 2(3), 31;

New Therapies of Neovascular AMD—Beyond Anti-VEGFs

School of Optometry and Vision Science, University of New South Wales, Sydney 00098, Australia
Received: 10 June 2018 / Revised: 24 July 2018 / Accepted: 27 July 2018 / Published: 30 July 2018
(This article belongs to the Special Issue Age-Related Macular Degeneration)
Full-Text   |   PDF [536 KB, uploaded 30 July 2018]   |  


Neovascular age-related macular degeneration (nAMD) is one of the leading causes of blindness among the aging population. The current treatment options for nAMD include intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). However, standardized frequent administration of anti-VEGF injections only improves vision in approximately 30–40% of nAMD patients. Current therapies targeting nAMD pose a significant risk of retinal fibrosis and geographic atrophy (GA) development in nAMD patients. A need exists to develop new therapies to treat nAMD with effective and long-term anti-angiogenic effects. Recent research on nAMD has identified novel therapeutic targets and angiogenic signaling mechanisms involved in its pathogenesis. For example, tissue factor, human intravenous immune globulin, interferon-β signaling, cyclooxygenase-2 (COX-2) and cytochrome P450 monooxygenase lipid metabolites have been identified as key players in the development of angiogenesis in AMD disease models. Furthermore, novel therapies such as NACHT, LRR and PYD domains containing protein 3 (NLRP3) inflammasome inhibition, inhibitors of integrins and tissue factor are currently being tested at the level of clinical trials to treat nAMD. The aim of this review is to discuss the scope for alternative therapies proposed as anti-VEGFs for the treatment of nAMD. View Full-Text
Keywords: neovascular AMD; new therapies; anti-VEGFs; AMD signaling neovascular AMD; new therapies; anti-VEGFs; AMD signaling

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Yerramothu, P. New Therapies of Neovascular AMD—Beyond Anti-VEGFs. Vision 2018, 2, 31.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics



[Return to top]
Vision EISSN 2411-5150 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top